Pharmaceuticals Company Announces Acquisition of Receptor Antagonist Avexitide

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has recently announced the acquisition of avexitide from Eiger BioPharmaceuticals, Inc. Avexitide has already garnered considerable attention for its potential therapeutic benefits and has received designations from the U.S. Food and Drug Administration (FDA). This article delves into the details of the acquisition, the scientific background of avexitide, and the future plans for its development and clinical trials. $Amylyx Pharmaceuticals (AMLX.US)$